VP Business Development · ORAMED PHARMACEUTICALS INC. (ORMP)

Mark Hasleton

FY2019 is the first fiscal year CompBrief holds for Mark Hasleton as a named executive officer of ORAMED PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$178,745

Salary $114,118Stock awards $0

4th of 6 named executive officers at Oramed Pharmaceuticals by FY2019 total.

6 named officers on file for ORAMED PHARMACEUTICALS, FY2019

Mark Hasleton’s pay file — $29

  • 1 fiscal year of pay, line by line
  • ORMP’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ORAMED PHARMACEUTICALS’s whole pay program stands against its peers

  • ORAMED PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ORMP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 30, 2020 (DEF 14A).

Free

Get Mark Hasleton’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mark Hasleton compensation by year

ORAMED PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as ORAMED PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$114,118
Bonus$0
Stock awards$0
Option awards$45,677
Non-equity incentive$0
Pension and deferred compensation$0
All other$18,949
Total$178,745

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ORAMED PHARMACEUTICALS INC. DEF 14A filed June 30, 2020, accession 0001213900-20-016305, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ORAMED PHARMACEUTICALS INC. filed document, accession 0001213900-20-016305. Every figure is read from that document and cited to the page and table it appears in. Filed June 30, 2020.

ORAMED PHARMACEUTICALS’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Nadav KidronPresident and Chief Executive Officer and director (7)$1,551,095
Miriam KidronChief Scientific Officer and director (8)$616,166
Hilla EisenbergChief Financial Officer (9)$190,786
Mark Hasleton · this pageVP Business Development$178,745
Avraham GabayChief Financial Officer$115,491
Joshua HexterChief Operating & Business Officer (10)$61,870

The full ORAMED PHARMACEUTICALS compensation record

free company brief

This page is one person within ORAMED PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ORAMED PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ORAMED PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Hasleton's compensation dossier · One-time report. No refunds.